Positron emission tomography in the diagnosis and staging of lung cancer: A systematic, quantitative review

Lancet Oncology

Volumn 2, Issue 11, 2001, Pages 659-666

  Fischer, Barbara MB ^a   Mortensen, Jann ^a   Højgaard, Liselotte ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EVALUATION; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM CANCER; MEDICAL ASSESSMENT; MEDICAL INFORMATION; MEDICAL LITERATURE; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY;

EID: 0035188330     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00555-1     Document Type: Review

References (74)

1. Bronchogenic carcinoma
2. Incidence of lung cancer in Denmark: Historical and actual status
3. Applications of PET in lung cancer
4. Lungesygdomme
5. Positron emission tomography in lung cancer
6. Positron emission tomography: Methods and instrumentation
7. PET scans approved for detecting metastatic non-small-cell lung cancer
8. New techniques catch lung cancers earlier
9. Meta-analysis: Bias in location and selection of sudies
10. Rationel Klinik, Evidensbaserede diagnostiske og terapeutiske beslutninger
11. Evidence-based medicine: How to practice and teach EBM
12. Positron emission tomographic imaging with flurodeoxyglucose is efficacious in evaluating malignant pulmonary disease
13. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions
14. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma
15. Localized form of bronchioloalveolar carcinoma: FDG PET findings
16. Prospective investigation of positron emission tomography in lung nodules
17. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum
18. Controlled prospective study of positron emission tomography using glucose analogue [18F] fluorodeoxyglucose in the evaluation of pulmonary nodules
19. Likelihood of malignancy in a solitary pulmonary nodule: Comparison of Bayesian analysis and results of FDG-PET scan
20. Pulmonary abnormalities and PET data analysis: A retrospective study
21. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
22. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET
23. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography
24. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images
25. Evaluation of pulmonary lesions with FDG-PET: Comparison of findings in patients with and without a history of prior malignancy
26. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer
27. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: A comparative risk-benefit analysis
28. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
29. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)
30. Characterization of chest masses by FDG positron emission tomography
31. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose
32. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities
33. Fluoro-déoxy-glucose et cancer bronchopulmonaire: Les premiers résultats francais en caméra à positions
34. Improvement of non-small-cell lung cancer staging by means of positron emission tomography
35. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer
36. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
37. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma
38. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
39. Selective use of PET scan in the preoperative staging of NSCLC
40. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients
41. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?
42. Detection of extrathoracic metastases by positron emission tomography in lung cancer
43. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer
44. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography
45. Lymph node staging in non-small cell lung cancer: Evaluation by [18F] FDG positron emission tomography (PET)
46. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping
47. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer
48. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography
49. Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer
50. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography
51. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
52. Mediastinal staging of non-small-cell lung cancer with positron emission tomography
53. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma
54. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging
55. Whole-body 18F-flurodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
56. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation
57. Diagnostische aussagekraft der positronen-emissions-tomographie (PET) bei zerebralen metastasen von bronchialkarzinomen
58. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: Comparison with FDG PET
59. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: Comparison of dual-head gamma camera in coincidence mode with a full-ring positron emission tomograpy system
60. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma camera
61. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer
62. FDG SPECT in patients with lung masses
63. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer
64. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner
65. Pumonary nodules: Differential diagnosis using 18F-fluorodeoxyglucose single-photon emission computed tomography
66. 18FDG beim primären Staging von Lungentumoren-Ergebnisse an einer Gammakamera mit einem 511 keV Kollimator
67. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytical comparison of PET and CT
68. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
69. Analytical decision model for the cost-effective management of solitary pulmonary nodules
70. Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma
71. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: A decision analysis based on cost reimbursement in Germany